Brunner Thomas B
Department of Radiation Oncology, University Medical Center Freiburg, Robert-Koch-Str. 3, Freiburg, Germany; German Cancer Consortium (DKTK), Freiburg, Germany.
Best Pract Res Clin Gastroenterol. 2016 Aug;30(4):515-28. doi: 10.1016/j.bpg.2016.07.002. Epub 2016 Jul 22.
This article aims to review the rationale behind the combination of radiotherapy and chemotherapy. Theoretical concepts describing the principles of the joint effects of chemoradiotherapy are reviewed. Preclinical and clinical evidence are collected and summarised demonstrating the co-operation between the two modalities which form the mainstay of the treatment of most solid tumours. Initially, the evolution of chemoradiotherapy was mostly empirically driven which is true for both, the early studies and the experimental investigations, rather than relying on scientific rationale. To date, the revised Steel's model proposes five mechanisms, spatial cooperation, cytotoxic enhancement, biological co-operation, temporary modulation and normal tissue protection to describe the interaction between radiotherapy and chemotherapy. Chemoradiotherapy has become the standard modality for most patients with locally advanced solid tumours due to better control of loco-regional disease and prolonged survival. Gradually, molecular prediction of efficacy is integrated such as MGMT status for combining temozolomide with radiotherapy in glioblastoma. As molecular targeted drugs are ready to be taken into triple combinations with chemoradiotherapy it is crucial to have a good understanding of the mechanisms of chemoradiotherapy for the rational development of future combinations.
本文旨在综述放疗与化疗联合应用的理论依据。回顾了描述放化疗联合效应原理的理论概念。收集并总结了临床前和临床证据,证明了这两种治疗方式之间的协同作用,它们构成了大多数实体瘤治疗的主要支柱。最初,放化疗的发展大多是由经验驱动的,早期研究和实验研究都是如此,而不是依靠科学原理。迄今为止,修订后的斯蒂尔模型提出了五种机制,即空间协同、细胞毒性增强、生物协同、暂时调节和正常组织保护,以描述放疗与化疗之间的相互作用。由于对局部区域疾病的更好控制和生存期的延长,放化疗已成为大多数局部晚期实体瘤患者的标准治疗方式。逐渐地,疗效的分子预测被纳入其中,例如在胶质母细胞瘤中,将替莫唑胺与放疗联合应用时的O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)状态。随着分子靶向药物准备与放化疗进行三联联合应用,为合理开发未来的联合方案,深入了解放化疗的机制至关重要。